FDA authorizes new treatment for migraine

The Food and Drug Administration Oct. 11 approved a new tablet for the acute treatment of migraine headache pain. Reyvow, or lasmiditan, is effective for migraine with or without aura, which appears as flashing lights or temporary loss of vision. While not meant as a preventive treatment, studies showed the tablet resolved pain and symptoms within two hours in many of the test patients. Migraine headaches affect one in seven Americans. “We know that the migraine community is keenly interested in additional treatment options,” said Nick Kozauer, M.D., acting deputy director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. “We remain committed to continuing to work with stakeholders to promote the development of new therapies for the acute and preventive treatment of migraine.”